Stay updated with breaking news from Jonathan Sadeh. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sustained efficacy was confirmed with an annualized relapse rate of 0.098 and 67% of patients were relapse-free at six years Safety was consistent with prior findings and the established safety...
Results provide the first clinical evidence to suggest that afimetoran may offer a benefit to patients with cutaneous lupus erythematosus.
Results show 26 weeks of treatment with twice-daily 60 mg dose of BMS-986278 resulted in a 69% relative reduction in the rate of decline in percent predicted forced vital capacity versus placeboTreatment effect was consistent with or without background therapy and BMS-986278 was well tolerated, with rates of adverse...
PRINCETON, N.J.--(BUSINESS WIRE)--Sep 9, 2023--
Results show 26 weeks of treatment with twice-daily 60 mg dose of BMS-986278 resulted in a 69% relative reduction in the rate of decline in percent predicted forced vital capacity versus...